Evidence map›Paper›PMID 31844962›Full record

ArticleEuropean radiology2020

Comparison of ferumoxytol- and gadolinium chelate-enhanced MRI for assessment of sarcomas in children and adolescents.

Florian Siedek, Anne M Muehe, Ashok J Theruvath, Raffi Avedian, Allison Pribnow, Sheri L Spunt, Tie Liang, Crystal Farrell, Heike E Daldrup-Link

Open access · greenAbstract readComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Article in European radiology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
2.4field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 16 citations in OpenAlex.

  1. Trial
  2. Review
  3. Article
  4. Article
  5. RSC advances · 2022
    Article
  6. Review
  7. Review
  8. Article
  9. Review
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 2 countries.

Florian SiedekDepartment of Radiology, Pediatric Molecular Imaging Program at Stanford (PedsMIPS), Stanford University, Stanford, CA, USA.
Anne M MueheDepartment of Radiology, Pediatric Molecular Imaging Program at Stanford (PedsMIPS), Stanford University, Stanford, CA, USA.
Ashok J TheruvathDepartment of Radiology, Pediatric Molecular Imaging Program at Stanford (PedsMIPS), Stanford University, Stanford, CA, USA.
Raffi AvedianDepartment of Orthopedic Surgery, Stanford University, Stanford, CA, USA.
Allison PribnowDepartment of Pediatrics, Hematology and Oncology, Lucile Packard Children's Hospital, Stanford University, Stanford, CA, USA.
Sheri L SpuntDepartment of Pediatrics, Hematology and Oncology, Lucile Packard Children's Hospital, Stanford University, Stanford, CA, USA.
Tie LiangDepartment of Radiology, Pediatric Molecular Imaging Program at Stanford (PedsMIPS), Stanford University, Stanford, CA, USA.
Crystal FarrellDepartment of Radiology, Pediatric Molecular Imaging Program at Stanford (PedsMIPS), Stanford University, Stanford, CA, USA.
Heike E Daldrup-LinkDepartment of Radiology, Pediatric Molecular Imaging Program at Stanford (PedsMIPS), Stanford University, Stanford, CA, USA. heiked@stanford.edu.ORCID http://orcid.org/0000-0002-4929-819X
Stanford University · USLucile Packard Children's Hospital · USJohannes Gutenberg University Mainz · DEUniversity of Cologne · DE

Funding

Personalized Whole Body Staging for Children with Cancer: A Solution to the Conundrum of Long-Term Side Effects from CT and PET/CT ScansR01HD081123 · NICHD · STANFORD UNIVERSITY · PI DALDRUP-LINK, HEIKE ELIZABETH · 2015 to 2019
$2.5M
NICHD NIH HHS R01 HD081123
6 · The paper itself

Abstract

objectivesWe compared the value of ferumoxytol (FMX)- and gadolinium (Gd)-enhanced MRI for assessment of sarcomas in paediatric/adolescent patients and hypothesised that tumour size and morphological features can be equally well assessed with both protocols.

methodsWe conducted a retrospective study of paediatric/adolescent patients with newly diagnosed bone or soft tissue sarcomas and both pre-treatment FMX- and Gd-MRI scans, which were maximal 4 weeks apart. Both protocols included T1- and T2-weighted sequences. One reader assessed tumour volumes, signal-to-noise ratios (SNR) of the primary tumour and adjacent tissues and contrast-to-noise ratios (CNR) of FMX- and Gd-MRI scans. Additionally, four readers scored FMX- and Gd-MRI scans according to 15 diagnostic parameters, using a Likert scale. The results were pooled across readers and compared between FMX- and Gd-MRI scans. Statistical methods included multivariate analyses with different models.

resultsTwenty-two patients met inclusion criteria (16 males, 6 females; mean age 15.3 ± 5.0). Tumour volume was not significantly different on T1-LAVA (p = 0.721), T1-SE (p = 0.290) and T2-FSE (p = 0.609) sequences. Compared to Gd-MRI, FMX-MRI demonstrated significantly lower tumour SNR on T1-LAVA (p < 0.001), equal tumour SNR on T1-SE (p = 0.104) and T2-FSE (p = 0.305), significantly higher tumour-to-marrow CNR (p < 0.001) on T2-FSE as well as significantly higher tumour-to-liver (p = 0.021) and tumour-to-vessel (p = 0.003) CNR on T1-LAVA images. Peritumoural and marrow oedema enhanced significantly more on Gd-MRI compared to FMX-MRI (p < 0.001/p = 0.002, respectively). Tumour thrombi and neurovascular bundle involvement were assessed with a significantly higher confidence on FMX-MRI (both p < 0.001).

conclusionsFMX-MRI provides equal assessment of the extent of bone and soft tissue sarcomas compared to Gd-MRI with improved tumour delineation and improved evaluation of neurovascular involvement and tumour thrombi. Therefore, FMX-MRI is a possible alternative to Gd-MRI for tumour staging in paediatric/adolescent sarcoma patients. KEY POINTS: • Ferumoxytol can be used as an alterative to gadolinium chelates for MRI staging ofpaediatric sarcomas. • Ferumoxytol-enhanced MRI provides equal assessment of tumour size and other diagnostic parameters compared to gadolinium chelate-enhanced MRI. • Ferumoxytol-enhanced MRI provides improved delineation of sarcomas from bone marrow, liver and vessels compared to gadolinium chelate-enhanced MRI.

Indexed as

AdolescentAdultChelating AgentsChildContrast MediaFemaleFerrosoferric OxideGadolinium DTPAHematinicsHumansMagnetic Resonance ImagingMaleRetrospective StudiesSarcomaYoung AdultChelating AgentsContrast MediaFerrosoferric OxideGadolinium DTPAHematinicsFerumoxytolGadoliniumMagnetic resonance imagingNanoparticlesSarcomas

Identifiers

PMID31844962
PMCPMC7035151
OpenAlexW2996206949

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.